Salivary gland pathology

2021 Insights on Keratoconjunctivitis Drugs in Development - ResearchAndMarkets.com

Retrieved on: 
Wednesday, July 28, 2021

The "Keratoconjunctivitis (Ophthalmology) - Drugs in Development, 2021" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Keratoconjunctivitis (Ophthalmology) - Drugs in Development, 2021" report has been added to ResearchAndMarkets.com's offering.
  • The report provides comprehensive information on the therapeutics under development for Keratoconjunctivitis, complete with analysis by Stage of Development, Drug Target, Mechanism of Action (MoA), Route of Administration (RoA) and Molecule Type.
  • Additionally, the report provides an overview of key players involved in therapeutic development for Keratoconjunctivitis and features dormant and discontinued projects.
  • The report reviews key players involved in the development of Keratoconjunctivitis (Ophthalmology) therapeutics and enlists all their major and minor projects.

Global Sjogren's Syndrome Acids Market (2020 to 2026) - Featuring AbbVie, Amgen and Biogen Among Others - ResearchAndMarkets.com

Retrieved on: 
Tuesday, July 6, 2021

Sjogren also affects the other parts of the body such as kidneys, joints, lungs, nerves, blood vessels.

Key Points: 
  • Sjogren also affects the other parts of the body such as kidneys, joints, lungs, nerves, blood vessels.
  • The factors contributing to the market growth include a growing population with several diseases that can cause Sjogren's syndrome and increasing demand for advanced treatment for Sjogren's syndrome.
  • However, a lack of awareness among the population about Sjogren's syndrome restrains the growth of the market.
  • market.

Salivary Bioscience Studies That Have Impact: Getting Back to Our ABCDs

Retrieved on: 
Wednesday, May 12, 2021

"\nAlthough COVID-19 has dominated much of the story of saliva over the last year, the ABCD study is a reminder that Salivary Bioscience makes a positive impact outside of COVID-19.

Key Points: 
  • "\nAlthough COVID-19 has dominated much of the story of saliva over the last year, the ABCD study is a reminder that Salivary Bioscience makes a positive impact outside of COVID-19.
  • Baseline data, such as the association between body mass index and hormone levels, has already been generated from this study.
  • "Salimetrics is ready with the experience and the latest knowledge in salivary bioscience," says Dr. Gaitonde.
  • "\nSalimetrics\' assay kits and CLIA-certified testing services are used to measure salivary analytes related to stress, behavior and development, inflammation, sleep, reproduction, health and immune function.

Global Dry Eye Epidemiology and Patient Flow Report 2021: Prevalence and Incidence and Patient by Age-Gender 2020-2035 - ResearchAndMarkets.com

Retrieved on: 
Thursday, May 6, 2021

b'The "Global Dry Eye Epidemiology and Patient Flow - 2021" report has been added to ResearchAndMarkets.com\'s offering.\nThe research report, Global Dry Eye Epidemiology and Patient Flow Analysis - 2021, provides Dry Eye epidemiology, demographics, and patient flow.

Key Points: 
  • b'The "Global Dry Eye Epidemiology and Patient Flow - 2021" report has been added to ResearchAndMarkets.com\'s offering.\nThe research report, Global Dry Eye Epidemiology and Patient Flow Analysis - 2021, provides Dry Eye epidemiology, demographics, and patient flow.
  • The data is presented by Pharma G7 countries including the US, France, Spain, Italy, UK, Japan.\nThe research provides population data to characterize Dry Eye patients, history of the disease at the population level (Dry Eye prevalence, Dry Eye incidence) and at the clinical level (from diagnosis to treated patients).
  • It also helps to identify patient sub-groups (age, gender, sub-groups) to understand targeted population for research and development, commercialization.\nDemographics: Dry Eye patients by age group, gender\nThe data from this research will help executives:\nEstablish basis for Dry Eye market sizing, assessing market potential, and developing drug forecast models\nIdentify Dry Eye patients segments through age groups, gender, and disease sub-types\nEvaluate Dry Eye market opportunities, identify target patient population\nView source version on businesswire.com: https://www.businesswire.com/news/home/20210506005581/en/\n'

Lantheus Grants Allegheny Health Network Exclusive Rights for the Use of its Microbubbles in Combination with Ultrasound Assisted Gene Therapy for the Development of a Proposed Treatment for Xerostomia

Retrieved on: 
Friday, April 30, 2021

Xerostomia is a chronic and debilitating condition with limited treatment options for patients,\xe2\x80\x9d said Mary Anne Heino, President and Chief Executive Officer of Lantheus.

Key Points: 
  • Xerostomia is a chronic and debilitating condition with limited treatment options for patients,\xe2\x80\x9d said Mary Anne Heino, President and Chief Executive Officer of Lantheus.
  • AHN will be solely responsible for all development work, future regulatory submissions and commercialization.
  • For more information, please visit www.lantheus.com .\nAllegheny Health Network ( AHN.org ) is an integrated healthcare delivery system serving the greater Western Pennsylvania region.
  • The inclusion of forward-looking statements should not be regarded as a representation that such plans, estimates and expectations will be achieved.

Soligenix Announces Presentations at Prominent Scientific Conferences

Retrieved on: 
Tuesday, April 13, 2021

Attendees can register here .\nHyBryte (SGX301) is a novel, first-in-class, photodynamic therapy utilizing safe, visible light for activation.

Key Points: 
  • Attendees can register here .\nHyBryte (SGX301) is a novel, first-in-class, photodynamic therapy utilizing safe, visible light for activation.
  • Combined with photoactivation, hypericin has demonstrated significant anti-proliferative effects on activated normal human lymphoid cells and inhibited growth of malignant T-cells isolated from CTCL patients.
  • In the first double-blind treatment cycle, 116 patients received HyBryte treatment (0.25% synthetic hypericin) and 50 received placebo treatment of their index lesions.
  • Unless required by law, Soligenix assumes no obligation to update or revise any forward-looking statements as a result of new information or future events.\n'

2021 Insights on Sjogren's Syndrome (SS) - Opportunity Analysis and Forecasts to 2029 - ResearchAndMarkets.com

Retrieved on: 
Wednesday, March 17, 2021

The "Sjogren's Syndrome (SS) - Opportunity Analysis and Forecasts to 2029" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Sjogren's Syndrome (SS) - Opportunity Analysis and Forecasts to 2029" report has been added to ResearchAndMarkets.com's offering.
  • Sjogren's syndrome (SS) is a chronic and systemic autoimmune inflammatory disorder in which an initial immunological attack that primarily targets the lacrimal and salivary glands.
  • In this report, the publisher analyses the current symptomatic SS treatment landscape and provides detailed insights into the market dynamics of this systemic autoimmune disease.
  • The launches of products with demonstrated efficacy will be a major driver of growth over the next 10 years.

United States Sjogren's Syndrome Market and Competitive Landscape 2017-2026 - ResearchAndMarkets.com

Retrieved on: 
Friday, February 12, 2021

The "US Sjogren's Syndrome Market and Competitive Landscape - 2021" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "US Sjogren's Syndrome Market and Competitive Landscape - 2021" report has been added to ResearchAndMarkets.com's offering.
  • US Sjogren's Syndrome Market and Competitive Landscape Highlights - 2021, provides comprehensive insights into Sjogren's Syndrome pipeline products, Sjogren's Syndrome epidemiology, Sjogren's Syndrome market valuations and forecast, Sjogren's Syndrome drugs sales and competitive landscape in the US.
  • Sjogren's Syndrome pipeline: Find out the products in clinical trials for the treatment of Sjogren's Syndrome by development phase 3, phase 2, and phase 1, by pharmacological class and companies developing the products
    Sjogren's Syndrome drugs: Identify key products marketed and prescribed for Sjogren's Syndrome in the US, including trade name, molecule name, and company
    Sjogren's Syndrome market valuations: Find out the market size for Sjogren's Syndrome drugs in 2019 in the US.
  • Find out how the market advanced from 2017 and forecast to 2026
    Sjogren's Syndrome drugs market share: Find out the market shares for key Sjogren's Syndrome drugs in the US
    Evaluate commercial market opportunity assessment, positioning, and segmentation for Sjogren's Syndrome products

Ocular Therapeutix™ Announces Upcoming Presentation of Interim OTX-TKI Phase 1 Clinical Trial Data at Angiogenesis, Exudation, and Degeneration 2021 – Virtual Edition

Retrieved on: 
Friday, February 12, 2021

We are particularly encouraged with the interim data presented to date from the Phase 1 trial.

Key Points: 
  • We are particularly encouraged with the interim data presented to date from the Phase 1 trial.
  • The presentation can be accessed February 13th on the Events and Presentations section of the Ocular Therapeutix website.
  • Ocular Therapeutixs first commercial drug product, DEXTENZA, is FDA-approved for the treatment of ocular inflammation and pain following ophthalmic surgery.
  • Ocular Therapeutix is currently evaluating OTX-CSI (cyclosporine intracanalicular insert) for the chronic treatment of dry eye disease in a Phase 2 clinical trial.

Aldeyra Therapeutics Announces Positive Top-Line Symptom and Sign Results from Run-In Cohort of Phase 3 TRANQUILITY Trial in Dry Eye Disease

Retrieved on: 
Thursday, January 7, 2021

Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today announced positive top-line symptom, redness, and Schirmers test results from the run-in cohort of the Phase 3 TRANQUILITY clinical trial in patients with dry eye disease.

Key Points: 
  • Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today announced positive top-line symptom, redness, and Schirmers test results from the run-in cohort of the Phase 3 TRANQUILITY clinical trial in patients with dry eye disease.
  • Consistent with previously announced allergen chamber Phase 2 clinical trial results, reproxalap demonstrated statistically significant improvement over vehicle (p = 0.03) in ocular redness, an objective sign of dry eye disease.
  • Among many patients and physicians, current dry eye disease therapies are considered inadequate.
  • In patients with dry eye disease, pro-inflammatory RASP may contribute to ocular inflammation and changes in tear lipid composition.